Trial Watch No. 14
A New Mega-Trial Record in Atrial Fibrillation
Where conviction is building in clinical development, in real time. Regeneron opened ROXI-EVEREST, the largest atrial fibrillation Phase 3 ever registered at 15,364 patients, testing REGN7508 (anti-Factor XI monoclonal antibody) vs. apixaban for stroke and systemic embolism prevention. MASH reaches Phase 3 in F4 compensated cirrhosis for the first time at scale, and post-CAR-T supportive care gets its first Phase 3.
Summary Layer
The second half of July 2026 sets a new mega-trial record. Regeneron opened ROXI-EVEREST, the largest atrial fibrillation Phase 3 ever registered at 15,364 patients, testing REGN7508 (anti-Factor XI monoclonal antibody) vs. apixaban for stroke and systemic embolism prevention. Combined with ROXI-PALISADE (PAD, 7,050 pts) and ROXI-CAT-II (cancer-associated VTE, 1,600 pts), Regeneron's single-antibody FXI program now exceeds 24,000 patients across three indications; the most concentrated anticoagulant investment in modern pharma history.
MASH reaches Phase 3 in F4 compensated cirrhosis for the first time at scale. GSK opens NEBULA-1 (Efimosfermin Alfa, 1,740 patients) and companion NEBULA-2 (F4 fibrosis, 380 patients); the FGF21 analog inherited via the 89bio acquisition entering Phase 3 in the hardest MASH population. Meanwhile Amgen's MariTide long-term extension Phase 3s (3,200 pts + 950 pts in obesity ± T2D) mark obesity's transition into real-world durability territory.
Post-CAR-T supportive care gets its first Phase 3. CSL Behring's IgPro20 in secondary immunodeficiency from CAR-T + BiTE therapy is the first pivotal trial addressing hypogammaglobulinemia as a consequence of scaling cell therapy volumes. 15 high-signal trials across oncology, cardiometabolic, immunology, neurology, and advanced modalities.
Therapeutic Areas Covered
Oncology
5 trialsAdjuvant Datopotamab Deruxtecan + Rilvegostomig vs. Investigator's Choice in High-Risk MIBC
Phase 3 · Oncology; adjuvant MIBC
Timeline
Start July 16, 2026; Primary completion September 2030
Mechanism
Dato-DXd (TROP2-directed ADC with deruxtecan payload) combined with rilvegostomig (AZ's PD-1xTIGIT bispecific) vs. investigator's choice (durvalumab, nivolumab, pembrolizumab, enfortumab vedotin) in adjuvant high-risk muscle-invasive urothelial carcinoma.
Why It Matters
Dato-DXd + rilvegostomig combination; AZ's TROP2 ADC platform meets its next-gen PD-1xTIGIT bispecific in the curative-intent bladder setting. 915 patients, 160 sites globally. AZ is placing both its bispecific IO and TROP2 ADC franchises into the same adjuvant program, positioning for combination-label approval.
Pivekimab Sunirine + Venetoclax + Azacitidine in Newly Diagnosed AML (Intensive Chemo-Ineligible)
Phase 2/3 · Oncology; newly diagnosed AML
Timeline
Start July 22, 2026; Primary completion June 2032
Mechanism
Pivekimab Sunirine (PVEK) is AbbVie's CD123-directed ADC with a DGN549 (IGN) DNA-alkylating payload, added to the ven/aza backbone in newly diagnosed AML unfit for intensive chemotherapy.
Why It Matters
Ven/aza has been the ineligible-AML standard since 2018. Adding an ADC layer targeting CD123 (highly expressed on AML blasts and leukemic stem cells) is the first attempt to escalate ven/aza with a targeted agent at Phase 3 scale. If the readout hits, ineligible AML gets a new triplet standard; and CD123 ADC opens toward BPDCN, MDS, and CMML.
Verified sources
Vorasidenib + Radiotherapy + Adjuvant Temozolomide vs. RT + TMZ in Newly Diagnosed IDH-Mutant Grade 3 Astrocytoma
Phase 3 · Oncology; IDH-mutant grade 3 astrocytoma
Timeline
Start July 20, 2026; Primary completion May 2033
Mechanism
Vorasidenib (Servier's oral IDH1/IDH2 inhibitor, approved 2024 in Grade 2 glioma via INDIGO trial) moves into Grade 3 astrocytoma; combined with post-RT adjuvant temozolomide.
Why It Matters
INDIGO changed low-grade glioma treatment in 2024. This Phase 3 tests whether vorasidenib can extend that benefit into higher-grade IDH-mutant tumors; where the malignant biology is more aggressive but IDH remains a driver. Positive readout would establish vorasidenib as the first genotype-directed CNS oncology drug across the full IDH-mutant spectrum.
Verified sources
IBI363 (PD-1/IL-2 Bispecific) + Bevacizumab vs. Investigator's Choice in Refractory Advanced CRC
Phase 3 · Oncology; refractory CRC
Timeline
Start July 20, 2026; Primary completion October 2028
Mechanism
IBI363 is Innovent's first-in-class PD-1/IL-2 bispecific fusion protein; PD-1 blockade linked to a low-affinity α-bias IL-2 that expands tumor-infiltrating CD8+ T cells. Combined with bevacizumab in patients who have failed standard care in advanced colorectal cancer.
Why It Matters
First Phase 3 of a PD-1/IL-2 bispecific in any indication. Novartis (COS-101), Roche (Cergutuzumab amunaleukin), and Merck have all attempted IL-2 fusion approaches with limited late-stage success. Innovent's α-bias IL-2 design is the cleanest attempt at the class. Positive readout in refractory MSS CRC; one of oncology's hardest indications; would validate the entire IL-2 fusion category.
Verified sources
TR115 vs. Investigator's Choice in Relapsed/Refractory Peripheral T/NK-Cell Lymphoma
Phase 3 · Oncology; r/r PTCL / NK/T-cell lymphoma
Timeline
Start July 30, 2026; Primary completion July 2029
Mechanism
TR115 is Tarapeutics's asset for r/r peripheral T-cell and NK-cell lymphoma (target undisclosed in public registration). Tests against investigator's choice chemo.
Why It Matters
Peripheral T-cell lymphomas remain among the most under-served hematologic malignancies. Belinostat, pralatrexate, romidepsin, and mogamulizumab deliver modest benefit; brentuximab vedotin is limited to CD30+ subtypes. A new class-agnostic asset reaching Phase 3 in this population expands options in a therapeutic corner where they're historically scarce.
Verified sources
Cardiometabolic
5 trialsROXI-EVEREST; REGN7508 vs. Apixaban for Stroke/SE Prevention in Atrial Fibrillation
Phase 3 · Cardiometabolic; atrial fibrillation
Timeline
Start July 31, 2026; Primary completion September 2029
Mechanism
REGN7508 (Regeneron's anti-Factor XI monoclonal antibody, same molecule as ROXI-PALISADE and ROXI-CAT-II) vs. apixaban for stroke and systemic embolism prevention in atrial fibrillation.
Why It Matters
The largest AF Phase 3 ever registered. Combined with ROXI-PALISADE (7,050 pts in PAD, Edition 10) and ROXI-CAT-II (1,600 pts in cancer VTE, Edition 12), Regeneron's single-antibody FXI program now exceeds 24,000 patients across three indications. This is the most concentrated anticoagulant investment in modern pharma history. If FXI wins on efficacy + bleeding reduction, apixaban's $10B franchise faces a class-succession event.
Verified sources
NEBULA-1; Efimosfermin Alfa in Adults With Compensated Cirrhosis Due to MASH
Phase 3 · Cardiometabolic; MASH F4 compensated cirrhosis
Timeline
Start July 20, 2026; Primary completion July 2033
Mechanism
Efimosfermin Alfa is GSK's monthly-dosed FGF21 analog (BOS-580, inherited via the 89bio acquisition). Companion trial NEBULA-2 (380 pts) covers F4 fibrosis. Both target compensated cirrhosis from metabolic dysfunction-associated steatohepatitis.
Why It Matters
First large Phase 3 in MASH F4 compensated cirrhosis. Resmetirom (Rezdiffra, Madrigal) is approved only in non-cirrhotic MASH; cirrhotic patients remain untreated. FGF21 has the strongest biologic rationale for fibrosis reversal; efruxifermin (Akero), pegozafermin (89bio pre-GSK), and now efimosfermin all target this space, but efimosfermin's monthly dosing is a meaningful differentiator. Positive readout would establish GSK's MASH franchise via the 89bio deal and open a $10B+ cirrhotic population.
Verified sources
Maridebart Cafraglutide (MariTide) Long-Term Extension in Obesity or Overweight
Phase 3 · Cardiometabolic; obesity long-term extension
Timeline
Start July 29, 2026; Primary completion December 2027
Mechanism
Long-term extension of the Maridebart Cafraglutide (AMG 133 / MariTide); Amgen's monthly-dosed GLP-1R agonist / GIP receptor antagonist conjugate; in patients who completed the parent trial (Edition 10's Phase 3 switch-from-GLP-1).
Why It Matters
3,200-pt long-term extension in obesity + 950-pt in obesity/T2D; Amgen is pre-positioning MariTide for durability + safety label data at scale. The monthly dosing profile is MariTide's key differentiator vs. Wegovy (weekly) and Zepbound (weekly). Long-term extension data at 3,200 patients establishes MariTide as commercially viable for chronic weight management.
UNIGUIDE-2; UBT251 vs. Semaglutide in T2D on Metformin ± Sulfonylurea/SGLT2
Phase 3 · Cardiometabolic; T2D (head-to-head vs Semaglutide)
Timeline
Start July 30, 2026; Primary completion February 2028
Mechanism
UBT251 is UBT's GLP-1/glucagon/GIP triple agonist. UNIGUIDE-2 runs three doses vs. semaglutide head-to-head in T2D patients with inadequate glycemic control on metformin ± sulfonylurea/SGLT2 inhibitor.
Why It Matters
UBT is also running UBT251 dose-finding in obesity (Novo-sponsored trial NCT07668388, Edition 12). Now the T2D Phase 3 head-to-head against semaglutide, run as an active-comparator instead of placebo. Retatrutide (Lilly) is the only other triple agonist in late-stage development; UBT251 is Chinese biotech's response.
Verified sources
Olatorepatide (REGN9930); GLP-1/GIP Receptor Agonist Dose-Finding in Overweight/Obesity
Phase 2 · Cardiometabolic; obesity (Regeneron entry)
Timeline
Start July 29, 2026; Primary completion January 2028
Mechanism
Olatorepatide is Regeneron's investigational GLP-1/GIP dual receptor agonist; a subcutaneous once-weekly obesity asset. Multiple doses and titration algorithms tested in overweight/obese adults.
Why It Matters
Regeneron's first-declared solo obesity asset; arriving into a nine-sponsor market (Novo, Lilly, Amgen, Pfizer, Roche, BI, Structure, AZ, and now Regeneron + UBT). GLP-1/GIP dual agonism is the tirzepatide (Lilly) framework; the question for Regeneron is whether its molecule can meaningfully differentiate on titration tolerability or dose ceiling.
Immunology
2 trialsAbbVie IBD Platform Basket; Risankizumab, Trosunilimab, ABBV-701 in Moderately-Severely Active Crohn's or UC
Phase 2 · Immunology; IBD platform basket
Timeline
Start July 24, 2026; Primary completion October 2031
Mechanism
Multi-arm platform basket testing AbbVie's IBD pipeline in parallel; risankizumab (Skyrizi, approved anti-IL-23), trosunilimab (novel), and ABBV-701; with shared placebo arms and adaptive arm-by-arm readouts in moderate-to-severe Crohn's and UC.
Why It Matters
Second major IBD platform trial in the Kitsa tracking window (Edition 11 balinatunfib Sanofi OLE was the first). Platform architecture accelerates pipeline decisions; AbbVie can move winners into Phase 3 and cut losers 12 to 18 months faster than traditional single-arm sequential trials. 2,000-patient enrollment signals AbbVie's confidence in extending Skyrizi's IBD franchise via combination and next-gen assets.
Verified sources
Rozanolixizumab Long-Term Open-Label Extension in Adults With Ocular Myasthenia Gravis
Phase 3 · Immunology; ocular myasthenia gravis (OLE)
Timeline
Start July 27, 2026; Primary completion January 2031
Mechanism
Long-term OLE of rozanolixizumab (Rystiggo, UCB's approved FcRn inhibitor) in patients who completed the parent OMG Phase 3 (Edition 10's Rystiggo OMG registration trial NCT07463521). Provides multi-year safety and durability data.
Why It Matters
UCB continues to build the ocular MG evidence base with a follow-on extension; critical for gaining specialty payer coverage and expanding label into pediatric OMG. FcRn class competition (argenx Vyvgart, incoming Vyvgart-Hytrulo) is intensifying; long-term durability differentiates.
Neurology
1 trialAlzheimer's Disease Systematic Multi-Arm Adaptive Randomized Trial (SMART); Atomoxetine + Metformin Repurposing
Phase 3 · Neurology; Alzheimer's (platform trial)
Timeline
Start July 24, 2026; Primary completion March 2031
Mechanism
Adaptive multi-arm platform testing atomoxetine (norepinephrine reuptake inhibitor, approved for ADHD) and metformin (glucose regulator, approved for T2D); both with observational evidence of AD risk reduction; vs. placebo in MCI and Alzheimer's dementia.
Why It Matters
Third Alzheimer's platform trial in three editions (Aisen Tau ATP in Ed 12, Sanofi SAR448851 in Ed 13, UCL SMART in Ed 14). Platform designs are now the AD field's standard architecture. Repurposed cheap generic drugs (atomoxetine + metformin) targeting AD is a distinct pharmacoeconomic bet: if either wins, cognitive decline slows at a fraction of anti-amyloid antibody costs.
Verified sources
Advanced Modalities
2 trialsIgPro20 in Secondary Immune Deficiency Due to CAR-T + T-Cell Redirecting Therapy
Phase 3 · Adv. Modalities; supportive care post-CAR-T/BiTE
Timeline
Start July 24, 2026; Primary completion February 2029
Mechanism
Subcutaneous immunoglobulin (Hizentra, CSL's approved SC IgG replacement) tested in secondary immunodeficiency from B-cell-targeting CAR-T and T-cell redirecting therapies. First Phase 3 in this specific hypogammaglobulinemia population.
Why It Matters
As CAR-T and BiTE volumes scale (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma, plus rising BiTE approvals for teclistamab, talquetamab, elranatamab, mosunetuzumab, epcoritamab), secondary hypogammaglobulinemia is becoming a major post-treatment complication. This is the first Phase 3 addressing it as a distinct commercial category. CSL is positioning IgPro20 for the CAR-T/BiTE supportive care market; as cell therapy scales, this supportive care category scales with it.
Ramantamig + Prophylactic Tocilizumab for CRS Prevention in R/R Multiple Myeloma
Phase 2 · Adv. Modalities; bispecific CRS prevention
Timeline
Start July 20, 2026; Primary completion December 2027
Mechanism
Ramantamig is Janssen's next-generation BCMAxCD3 bispecific (target profile improved over teclistamab). Tested with prophylactic tocilizumab vs. placebo to prevent cytokine release syndrome (CRS) at first dose administration.
Why It Matters
First Phase 2 explicitly designed to test prophylactic tocilizumab for BiTE-associated CRS prevention. CRS remains the single biggest logistical barrier to outpatient BiTE administration in MM. If tocilizumab prophylaxis reduces CRS to manageable levels, teclistamab and ramantamig can move from inpatient step-up dosing into outpatient care; a fundamental cost and access shift.
Verified sources
Signal Convergence
Five patterns across the July 16 to 31 window
1. Regeneron's FXI antibody program crosses 24,000 patients
ROXI-EVEREST (AF, 15,364 pts) joins ROXI-PALISADE (PAD, 7,050 pts) and ROXI-CAT-II (cancer VTE, 1,600 pts). One antibody, three indications, three mega Phase 3s. The most concentrated anticoagulant investment in modern pharma history. Apixaban's $10B franchise faces a class-succession event.
2. MASH cirrhosis reaches Phase 3 at scale for the first time
GSK NEBULA-1 (1,740 pts) + NEBULA-2 (380 pts) in compensated cirrhosis (F4 fibrosis). Efimosfermin Alfa is the FGF21 analog inherited via the 89bio acquisition; first Phase 3 program targeting the cirrhotic MASH population that Rezdiffra doesn't cover.
3. Obesity moves into long-term extension + head-to-head architecture
Amgen MariTide extension (3,200 pts obesity + 950 pts obesity/T2D). UBT251 vs. Semaglutide Phase 3 head-to-head at 956 patients. Regeneron enters with Olatorepatide Phase 2. Obesity is now a nine-sponsor race (Novo, Lilly, Amgen, Pfizer, Roche, BI, Structure, AZ, Regeneron + UBT).
4. Post-CAR-T supportive care gets its first Phase 3
CSL Behring's IgPro20 in secondary immunodeficiency from CAR-T + BiTE therapy is the first pivotal trial addressing hypogammaglobulinemia as a distinct commercial category. Janssen's ramantamig + prophylactic tocilizumab for CRS prevention is the parallel move on the operational-cost side. Cell therapy is now scaled enough to have its own supportive care subcategory.
5. Alzheimer's platform trials become the field's standard
UCL SMART (atomoxetine + metformin repurposing, 1,200 pts) joins Edition 12's Aisen Tau ATP and Edition 13's Sanofi SAR448851 as the third AD platform trial in three editions. Repurposed generics + tau + novel mechanisms in parallel; the AD field is diversifying architecture beyond the anti-amyloid antibody thesis.
Underlying truth: the pharmaceutical industry is running the most operationally ambitious summer of clinical trials in a decade. 15,364-patient AF trials. 3,200-patient obesity extensions. 2,000-patient IBD basket trials. 1,740-patient cirrhosis Phase 3s. Mega-trial scale is no longer an outlier; it's the default architecture for franchise-defining programs.
Continue Tracking
Trial Watch is Kitsa's clinical intelligence layer. Edition 15 (August 1 to 15, 2026) drops on August 15.
On Verification
Every trial in this edition is anchored to the exact ClinicalTrials.gov record and one or more directly relevant secondary sources where available. Dead WHO ICTRP shell pages and generic sponsor homepages have been removed. Remaining links point to direct registry copies, sponsor trial pages, institutional trial pages, publication pages, or program sources that visibly support the listed trial, drug, NCT ID, acronym, sponsor, or program. All 15 trials in this edition have start dates verified to fall within July 16 to July 31, 2026, and none repeat from Editions 1 to 13 based on the supplied dedup history.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.